One year in review 2016: novelties in the treatment of rheumatoid arthritis.
Rheumatoid arthritis (RA) is a chronic disease characterised by inflammation of the synovial tissue in joints, which can lead to joint destruction. The primary goal of the treatment is to control pain and inflammation, reduce joint damage and disability, and maintain or improve physical function and quality of life. The present review is aimed at providing a critical analysis of the recent literature on the novelties in the treatment of RA, with a particular focus on the most relevant studies published over the last year.
Rheumatology Unit, Department of Experimental and Clinical Medicine, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Italy.
Andrea
A
Calabrò
Rheumatology Unit, Department of Experimental and Clinical Medicine, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Italy.
Anna Laura
AL
Caterino
Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
Elena
E
Elefante
Department of Rheumatology, University of Perugia, Italy.
Valentina
V
Valentini
Department of Rheumatology, Policlinico Le Scotte, University of Siena, Italy.
Antonio
A
Vitale
Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
Rosaria
R
Talarico
Department of Rheumatology, Policlinico Le Scotte, University of Siena, Italy. cantariniluca@hotmail.com.
Luca
L
Cantarini
Department of Rheumatology, Policlinico Le Scotte, University of Siena, Italy.
Bruno
B
Frediani
D018501:Antirheumatic Agents / Q000494:pharmacology*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology / Q000523:psychology; D001691:Biological Therapy / Q000379:methods*; D002986:Clinical Trials as Topic; D006801:Humans; D054539:Medication Therapy Management / Q000639:trends; D018579:Patient Selection; D011788:Quality of Life; D035703:Therapies, Investigational; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha